echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Alzheimer Dementia: What factors affect the amyloid markers in the blood?

    Alzheimer Dementia: What factors affect the amyloid markers in the blood?

    • Last Update: 2021-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2018, the National Institute of Aging and the Alzheimer's Association (NIA-AA) research framework proposed the AT(N) system as the biological definition of Alzheimer's (AD), based on amyloid (A) The pathological process of phosphorylated tau (T) and neurodegeneration (N)


    Given the invasive nature of obtaining CSF and the time and cost associated with neuroimaging, identifying biomarkers that are easier to obtain is an important goal


    Blood biomarkers for AD and other dementias are very suitable for screening or diagnosis in the population , as well as for continuous evaluation to track disease progression


    Screening diagnosis

    This is especially important for establishing the reference range


    It is important to understand whether levels vary with age and gender, or whether conditions such as chronic kidney disease (CKD) that can affect protein clearance should be considered



    They analyzed the plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40 ratio of 996 Mayo Clinic Aging Study (MCSA) participants aged 51 to 95 years on the Quanterix Simoa HD-1 analyzer ) To take a measurement


    They found that in the cognitively impaired (CU), all plasma markers were age-related


    For example, a higher Charlson comorbidity index and chronic kidney disease are associated with higher levels of all biomarkers


    The important significance of this study is to illustrate; multiple variables affect the plasma biomarkers of amyloid pathology and neurodegeneration in the general population


    Several variables influence the plasma biomarkers of amyloid pathology and neurodegeneration in CU in the general population





    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.